IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

C. N. Andreassen*, J. G. Eriksen, K. Jensen, C. R. Hansen, B. S. Sørensen, P. Lassen, J. Alsner, L. M.H. Schack, J. Overgaard, C. Grau

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Abstract

Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.
OriginalsprogEngelsk
TidsskriftOral Oncology
Vol/bind86
Sider (fra-til)91-99
Antal sider9
ISSN1368-8375
DOI
StatusUdgivet - 1 nov. 2018

Fingeraftryk

Dyk ned i forskningsemnerne om 'IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater